Gilead Reports Updated Results of Descovy in P-III DISCOVER Study for Pre-Exposure Prophylaxis of HIV

 Gilead Reports Updated Results of Descovy in P-III DISCOVER Study for Pre-Exposure Prophylaxis of HIV

Gilead Reports Updated Results of Descovy in P-III DISCOVER Study for Pre-Exposure Prophylaxis of HIV

Shots:

  • The P-III DISCOVER study involves assessing of Descovy (emtricitabine, 200 mg/tenofovir alafenamide, 25 mg, qd) vs Truvada (emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in adult male and transgender female with HIV PrEP
  • The P-III DISCOVER study results: met its 1EPs of non-inferiority, reduction in time to achieve EC90 of tenofovir diphosphate (TFV-DP) in PBMCs, @4wks. TFV-DP level (98% vs 68%). Additionally, pharmacokinetic data showed Descovy maintains TFV-DP conc. level for a longer time than Truvada
  • Descovy is a dual regimen therapy indicated in combination with other ARV for HIV-1 infections in patients weighing at least 35 kg

Click here to read full press release/ article | Ref: Gilead | Image:  STAT

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post